MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
588.36%
Quick Ratio
588.36%
Cash Ratio
530.53%
Debt to Asset Ratio
17.46%
Unit: Thousand (K) dollars
Assets Breakdown
Cash and cash equivalents
Research and development incenti...
Less accumulated depreciation
Others
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
30,118
36,223
40,992
48,698
Prepaid expenses and other current assets
1,600
2,249
2,531
2,694
Research and development incentives receivables
1,683
1,562
1,497
1,015
Total current assets
33,401
40,034
45,020
52,407
Property and equipment, at cost
1,072
1,069
1,222
1,221
Less accumulated depreciation
1,018
978
1,085
1,047
Property and equipment, net
54
91
137
174
Operating lease right-of-use assets, net
1,003
108
244
378
Intangible assets, net
256
381
516
643
Total assets
34,714
40,614
45,917
53,602
Accounts payable
1,121
3,226
1,333
879
Accrued expenses
2,455
2,046
2,026
4,118
Convertible loan notes - current
-
-
0
0
Operating lease liabilities - current
1,030
0
202
397
Other current liabilities
1,071
905
741
622
Total current liabilities
5,677
6,177
4,302
6,016
Warrant liabilities - non-current
15
21
38
336
Operating lease liabilities- non current
-
-
0
0
Other non-current liabilities
370
362
661
652
Total liabilities
6,062
6,560
5,001
7,004
Ordinary shares, par value 0.003 per share 798,093,044 shares issued at june 30, 2026 (december 31, 2025 795,658,504)
3,145
3,145
3,135
3,134
Additional paid-in capital
552,335
551,018
549,622
548,041
Accumulated deficit
-514,543
-507,538
-501,018
-493,667
Accumulated other comprehensive loss
-12,285
-12,571
-10,823
-10,910
Total shareholders' equity
28,652
34,054
40,916
46,598
Total liabilities and shareholders' equity
34,714
40,614
45,917
53,602
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$30,118K
(-46.34%↓ Y/Y)
Research and development
incentives receivables
$1,683K
(-38.82%↓ Y/Y)
Prepaid expenses and
other current assets
$1,600K
(-37.13%↓ Y/Y)
Property and equipment,
at cost
$1,072K
(-19.28%↓ Y/Y)
Total current assets
$33,401K
(-45.62%↓ Y/Y)
Operating lease
right-of-use assets, net
$1,003K
(92.15%↑ Y/Y)
Intangible assets, net
$256K
(-45.53%↓ Y/Y)
Property and equipment,
net
$54K
(-75.23%↓ Y/Y)
Less accumulated
depreciation
$1,018K
(-8.29%↓ Y/Y)
Total assets
$34,714K
(-44.57%↓ Y/Y)
Total liabilities and
shareholders' equity
$34,714K
(-44.57%↓ Y/Y)
Total shareholders'
equity
$28,652K
(-47.11%↓ Y/Y)
Total liabilities
$6,062K
(-28.29%↓ Y/Y)
Accumulated deficit
-$514,543K
(-5.73%↓ Y/Y)
Accumulated other
comprehensive loss
-$12,285K
(-42.14%↓ Y/Y)
Additional paid-in capital
$552,335K
(1.10%↑ Y/Y)
Total current
liabilities
$5,677K
(-24.88%↓ Y/Y)
Other non-current
liabilities
$370K
(5.11%↑ Y/Y)
Warrant liabilities -
non-current
$15K
(-97.25%↓ Y/Y)
Ordinary shares, par
value 0.003 per share...
$3,145K
(0.42%↑ Y/Y)
Accrued expenses
$2,455K
(-51.30%↓ Y/Y)
Accounts payable
$1,121K
(-1.49%↓ Y/Y)
Other current
liabilities
$1,071K
(37.84%↑ Y/Y)
Operating lease
liabilities - current
$1,030K
(71.38%↑ Y/Y)
Buy us a coffee
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)